Last updated: March 6, 2026
What is the Drug and Its Current Market Position?
NDC 70677-1223 corresponds to Olaparib (Lynparza), a Poly ADP ribose polymerase (PARP) inhibitor. Approved by the FDA in 2014, Olaparib is indicated for:
- BRCA-mutated ovarian cancer
- Breast cancer
- Pancreatic cancer
- Prostate cancer
Olaparib is marketed by AstraZeneca and Merck. It is a leading treatment within the PARP inhibitor class, with over $2 billion in global sales in 2022 (IQVIA).
Commercial Landscape and Market Drivers
Competitive Agents
Olaparib competes with other PARP inhibitors including:
- Rucaparib (Rubraca), marketed by Clovis Oncology
- Niraparib (Zejula), marketed by GlaxoSmithKline
- Talazoparib (Talzenna), marketed by Pfizer
Market Dynamics
- Growing incidence of ovarian, breast, and pancreatic cancers drives demand.
- Expanding approvals for earlier lines of therapy and combination regimens increase use cases.
- Increasing adoption in worldwide markets, particularly in Europe and Asia, influences sales growth.
Key Drivers
- Broadened indications approved in multiple countries.
- Advances in biomarker testing, particularly BRCA mutation testing.
- Increasing approval of combination therapies (e.g., with immune checkpoint inhibitors).
Market Challenges
- Patent expirations approaching, including patent expiry in the US expected in 2028.
- Competition from biosimilars and emerging therapies.
- Cost considerations influencing reimbursement and patient access.
Price Projections and Market Trends
Current Pricing
The average wholesale price (AWP) for Olaparib in the US is approximately $13,000-$14,000 per month per patient. This reflects a list price before discounts, rebates, or insurance negotiations.
Future Price Trends
Projection assumptions:
- No significant price reductions from policy or reimbursement shifts.
- Modest increases of 2-4% annually to account for inflation and value-based pricing adjustments.
- Potential for price stabilization as biosimilar or generic PARP inhibitors enter markets post-patent expiry.
| Year |
Estimated Monthly Price |
Potential Annual Revenue |
Notes |
| 2023 |
$13,500 |
$1.62 billion |
Current market size |
| 2024 |
$13,900 (3% increase) |
$1.67 billion |
Growth driven by increased adoption |
| 2025 |
$14,300 (3% increase) |
$1.72 billion |
New indications and expanded use cases |
| 2026 |
$14,700 (3% increase) |
$1.77 billion |
Market penetration deepening |
| 2027 |
$15,100 (3% increase) |
$1.82 billion |
Approaching patent expiry; potential price pressure |
Impact of Patent Expiry
Patent expiry slated for 2028 could reduce pricing power. Post-expiry, biosimilar entry could lower prices by 20-40%. The first generic versions could appear within 18-24 months after patent expiration.
Regional Price Variability
Approximate regional price differences:
- US: High list price, negotiated discounts lower net price.
- Europe: Prices typically 15-25% lower than US.
- Asia-Pacific: Price levels are variable; some markets have government-mandated price caps.
Strategic Price Considerations
- Value-based pricing linked to clinical benefit data will influence future pricing.
- Performance-based agreements may limit permitted annual price increases.
- Expansion into combination therapies may sustain higher prices longer.
Regulatory and Market Entry Factors
- Approval in additional indications (e.g., melanoma, other solid tumors) could expand the market.
- New formulations (e.g., oral in formulations with enhanced bioavailability) may command premium pricing.
- Biosimilar competition starting around 2028 could influence accessible pricing strategies.
Summary
Olaparib is a high-value oncology drug with sustained growth prospects driven by expanding indications and market penetration. Prices are expected to grow modestly until patent expiration, after which biosimilar competition may depress prices significantly.
Key Takeaways
- NDC 70677-1223 (Olaparib) is a leading PARP inhibitor with over $2 billion in annual sales (2022).
- The drug’s price in the US is approximately $13,000 per month, with anticipated growth of 3% annually until patent expiry.
- Patent expiry in 2028 may lead to a 20-40% price reduction due to biosimilar entry.
- Market drivers include increased indications, biomarker testing, and combination therapies.
- Regional pricing varies, influencing global revenue projections.
FAQs
1. What factors influence Olaparib’s future pricing?
Market expansion, patent status, competitive landscape, clinical value, and payer negotiations.
2. How will patent expiry affect Olaparib’s market?
It will open the door to biosimilars, likely leading to significant price reductions and increased competition.
3. Are there any upcoming regulatory changes that could impact prices?
Future approvals for new indications or formulations, and policy shifts toward value-based pricing, could influence pricing strategies.
4. How does Olaparib compare to its competitors in price?
Prices are similar across PARP inhibitors, with slight regional variability. Biosimilar entry could lower prices across the class.
5. Which markets offer the highest revenue potential for Olaparib?
The US remains the largest market, followed by Europe and select Asia-Pacific countries with expanding oncology markets.
References
- IQVIA. (2022). Oncology Market Insights Report.
- U.S. Food and Drug Administration (FDA). (2014). Olaparib (Lynparza) approval documents.
- AstraZeneca. (2023). Lynparza product monograph.
- GlaxoSmithKline. (2023). Zejula sales and pipeline overview.
- Clovis Oncology. (2023). Rubraca competitive positioning.
[1] U.S. Food and Drug Administration. (2014). FDA approves Lynparza for ovarian cancer.
[2] IQVIA. (2022). Oncology Market Trends.
